| scholarly article | Q13442814 |
| P50 | author | Paul Devroey | Q7150251 |
| P2093 | author name string | Diedrich K | |
| Griesinger G | |||
| Kolibianakis EM | |||
| Schultze-Mosgau A | |||
| Schroer A | |||
| van Steirteghem A | |||
| P2860 | cites work | The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix | Q47719407 |
| Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists | Q48823831 | ||
| Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up | Q48846940 | ||
| A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization | Q49067046 | ||
| Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. | Q50671961 | ||
| Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. | Q50804422 | ||
| Experience with the elective transfer of two embryos under the conditions of the german embryo protection law: results of a retrospective data analysis of 2573 transfer cycles | Q33179630 | ||
| Luteal phase support in infertility treatment: a meta-analysis of the randomized trials | Q34803226 | ||
| Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome | Q35623466 | ||
| Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization | Q42166313 | ||
| Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix | Q43559187 | ||
| Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertil | Q44582470 | ||
| Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol | Q45234407 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase | Q47333299 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2887-2892 | |
| P577 | publication date | 2005-06-24 | |
| P1433 | published in | Human Reproduction | Q5937357 |
| P1476 | title | A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists | |
| P478 | volume | 20 |
| Q90259787 | A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL |
| Q38685318 | A fresh look at the freeze-all protocol: a SWOT analysis |
| Q48785786 | Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit? |
| Q46199929 | Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study |
| Q36966423 | Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study |
| Q35471131 | Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study |
| Q47950058 | Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study |
| Q48517030 | Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate |
| Q60921155 | Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve |
| Q55311441 | Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders |
| Q41612779 | Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study |
| Q37024897 | Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study |
| Q37994630 | Follicular determinants of pregnancy establishment and maintenance |
| Q38835475 | Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art. |
| Q33770533 | GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis |
| Q26800033 | GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis |
| Q36970343 | GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? |
| Q33226124 | GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis |
| Q28308094 | GnRH agonist for triggering of final oocyte maturation: time for a change of practice? |
| Q50641559 | GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. |
| Q41725757 | GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates |
| Q36570314 | GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation |
| Q28077044 | GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article |
| Q38222516 | GnRH agonist triggers and their use in assisted reproductive technology: the past, the present and the future |
| Q35112937 | GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells |
| Q41011753 | GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. |
| Q36957480 | GnRH analogues in the prevention of ovarian hyperstimulation syndrome |
| Q34573314 | GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis |
| Q90625275 | Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention |
| Q88990735 | Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles |
| Q24234765 | Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles |
| Q24236630 | Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles |
| Q24193015 | Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology |
| Q100523508 | Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction |
| Q52003232 | Gonadotropin-releasing hormone antagonist in in vitro fertilization superovulation. |
| Q37425142 | Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study |
| Q33799681 | Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial |
| Q37372180 | Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment |
| Q92106259 | In Freeze-All Strategy, Cumulative Live Birth Rate (CLBR) Is Increasing According to the Number of Blastocysts Formed in Women <40 Undergoing Intracytoplasmic Sperm Injection (ICSI) |
| Q45585806 | LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? |
| Q61443510 | Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clini |
| Q42950977 | Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist–triggered assisted reproductive technique cycles: understanding a new approach |
| Q48717966 | Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study |
| Q40278645 | Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study |
| Q41645905 | Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience |
| Q36970150 | Natural IVF cycles may be desirable for women with repeated failures by stimulated IVF cycles |
| Q57177405 | Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment |
| Q37709815 | OHSS Free Clinic |
| Q80292226 | One million and counting |
| Q44063499 | Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates |
| Q21245566 | Optimal usage of the GnRH antagonists: a review of the literature |
| Q34641919 | Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study |
| Q55279761 | Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. |
| Q26827593 | Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention |
| Q90593847 | Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes |
| Q34009789 | Pharmaceutical options for triggering of final oocyte maturation in ART |
| Q33743109 | Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature |
| Q38053144 | Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger |
| Q45301872 | Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. |
| Q42353679 | Recent advances in in vitro fertilization |
| Q59676551 | Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study |
| Q36847973 | Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome |
| Q28084432 | Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic |
| Q48606765 | Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. |
| Q48801571 | Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation |
| Q50646269 | Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols. |
| Q37539028 | Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? |
| Q34458877 | The Luteal Phase after GnRHa Trigger-Understanding An Enigma |
| Q36551246 | The classification, functions and clinical use of different isoforms of HCG. |
| Q38620147 | The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups |
| Q55255517 | The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS |
| Q33805486 | The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist |
| Q35540821 | The prevention of ovarian hyperstimulation syndrome |
| Q44996326 | The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles |
| Q36319447 | The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. |
| Q38954609 | The state of "freeze-for-all" in human ARTs |
| Q48643865 | Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial |
| Q35986810 | Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom? |
| Q33897147 | Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience |
| Q34928751 | Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial |
| Q81474129 | Use of GnRHa to induce ovulation in GnRH antagonist cycles |
| Q36900329 | Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome. |
Search more.